Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | BMP4 | P12644 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1750623 | 0.95 | CDK5 (0.40) | MAPTCHRNA7KMT2ALYNSRC | |
| SCHEMBL13338014 | 0.90 | BRAF (0.44) | KDRPARP1GSK3AGSK3BDYRK1A | |
| SCHEMBL1750600 | 0.88 | ALOX5 (0.43) | KDRPARP1GSK3AGSK3BDYRK1A | |
| SCHEMBL5563039 | 0.87 | GSK3A (0.43) | MAPTSRCKDRGSK3AGSK3B | |
| SCHEMBL1752472 | 0.83 | KDR (0.50) | KDRPARP1GSK3AGSK3BDYRK1A | |
| SCHEMBL1750936 | 0.82 | CDK5 (0.38) | PARP1GSK3AGSK3BDYRK1ACDK5 | |
| SCHEMBL1752097 | 0.82 | GSK3A (0.54) | MAPTKMT2ASRCKDRGSK3A | |
| SCHEMBL1750603 | 0.81 | KDR (0.47) | KDRBMP4DYRK1A | |
| SCHEMBL3424195 | 0.80 | ITK (0.40) | MAPTKMT2AKDRPARP1GSK3A | |
| SCHEMBL1750229 | 0.80 | KDR (0.55) | KDRPARP1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709466-B2 | Pyridazinone derivatives, methods for their production and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | claimed |
| US-20070259870-A1 | Novel Pyridazinone Derivatives | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | claimed |
| EP-1751141-A1 | NOVEL PYRIDAZINONE DERIVATIVES AS INHIBITORS OF CDK2 | Aventis Pharma S.A. (FR) | 2007-02-14 | — | — | EP | claimed |
| WO-2005111019-A1 | NOVEL PYRIDAZINONE DERIVATIVES AS INHIBITORS OF CDK2 | AVENTIS PHARMA S.A. (FR) | 2005-11-24 | — | — | WO | claimed |
| EP-1598348-A1 | Novel pyridazinone derivatives as inhibitors of CDK2 | Aventis Pharma Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | claimed |
| EP-1753743-B1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-7968546-B2 | Pyridazinone kinase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-7968546-B2 | Pyridazinone kinase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-7968546-B2 | Pyridazinone kinase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-7709466-B2 | Pyridazinone derivatives, methods for their production and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7709466-B2 | Pyridazinone derivatives, methods for their production and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7709466-B2 | Pyridazinone derivatives, methods for their production and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| EP-1753743-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-02-21 | — | — | EP | disclosed |
| EP-1751141-A1 | NOVEL PYRIDAZINONE DERIVATIVES AS INHIBITORS OF CDK2 | Aventis Pharma S.A. (FR) | 2007-02-14 | — | — | EP | disclosed |
| EP-1604988-A1 | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005111018-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005111019-A1 | NOVEL PYRIDAZINONE DERIVATIVES AS INHIBITORS OF CDK2 | AVENTIS PHARMA S.A. (FR) | 2005-11-24 | — | — | WO | disclosed |
| EP-1598348-A1 | Novel pyridazinone derivatives as inhibitors of CDK2 | Aventis Pharma Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | GSK3B, GSK3A, PDXK | MAPT 1093/4885CHRNA7 1462/4885KMT2A 3303/4885 |
| US-20070259870-A1 | Novel Pyridazinone Derivatives | CDK2, CDK1, CDK20 | MAPT 2764/4885CHRNA7 3931/4885KMT2A 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.